Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes

References

• Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A. (1993). Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707–715.
   PubMed Web of Science ®Google Scholar
• Aitken AE, Morgan ET. (2007). Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35:1687–1693.
   PubMed Web of Science ®Google Scholar
• Aouabdi S, Gibson G, Plant N. (2006). Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. Drug Metab Dispos 34:138–144.
   PubMed Web of Science ®Google Scholar
• Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK. (1991). The interferons. Mechanisms of action and clinical applications. JAMA 266:1375–1383.
   PubMed Web of Science ®Google Scholar
• Becquemont L, Chazouilleres O, Serfaty L, Poirier JM, Broly F, Jaillon P, Poupon R, Funck-Brentano C. (2002). Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther 71:488–495.
   PubMed Web of Science ®Google Scholar
• Bojes HK, Thurman RG. (1996). Peroxisome proliferators activate Kupffer cells in vivo. Cancer Res 56:1–4.
   PubMed Web of Science ®Google Scholar
• Brockmeyer NH, Barthel B, Mertins L, Goos M. (1998). Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta. Int J Clin Pharmacol Ther 36:309–311.
   PubMed Web of Science ®Google Scholar
• Byrnes AA, Li DY, Park K, Thompson D, Mocilnikar C, Mohan P, Molleston JP, Narkewicz M, Zhou H, Wolf SF, Schwarz KB, Karp CL. (2007). Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C. J Leukoc Biol 81:825–834.
   PubMed Web of Science ®Google Scholar
• Chetty M, Murray M. (2007). CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 8:307–313.
   PubMed Web of Science ®Google Scholar
• Craig PI, Mehta I, Murray M, McDonald D, Aström A, van der Meide PH, Farrell GC. (1990). Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver. Mol Pharmacol 38:313–318.
   PubMed Web of Science ®Google Scholar
• Dalen KT, Ulven SM, Arntsen BM, Solaas K, Nebb HI. (2006). PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. J Lipid Res 47:931–943.
   PubMed Web of Science ®Google Scholar
• Deterding K, Grüngreiff K, Lankisch TO, Potthoff A, Bahr MJ, Manns MP, Wedemeyer H, Strassburg CP. (2009). Gilbert’s syndrome and antiviral therapy of hepatitis C. Ann Hepatol 8:246–250.
   PubMed Web of Science ®Google Scholar
• Donato MT, Herrero E, Gómez-Lechón MJ, Castell JV. (1993). Inhibition of monooxygenase activities in human hepatocytes by interferons. Toxicol In Vitro 7:481–485.
   PubMed Web of Science ®Google Scholar
• Farrar MA, Schreiber RD. (1993). The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571–611.
   PubMed Web of Science ®Google Scholar
• Gordon CP, Keller PA. (2005). Control of hepatitis C: a medicinal chemistry perspective. J Med Chem 48:1–20.
   PubMed Web of Science ®Google Scholar
• Grubisic-Cabo F, Vrdoljak E. (2006). Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy. Med Oncol 23:121–124.
   PubMed Web of Science ®Google Scholar
• Ha HR, Chen J, Freiburghaus AU, Follath F. (1995). Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 39:321–326.
   PubMed Web of Science ®Google Scholar
• Haque SJ, Williams BR. (1998). Signal transduction in the interferon system. Semin Oncol 25:14–22.
   PubMed Web of Science ®Google Scholar
• Hasmall S, James N, Hedley K, Olsen K, Roberts R. (2001). Mouse hepatocyte response to peroxisome proliferators: dependency on hepatic nonparenchymal cells and peroxisome proliferator activated receptor alpha (PPARalpha). Arch Toxicol 75:357–361.
   PubMed Web of Science ®Google Scholar
• Hassan M, Nilsson C, Olsson H, Lundin J, Osterborg A. (1999). The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. Eur J Haematol 63:163–170.
   PubMed Web of Science ®Google Scholar
• Islam M, Frye RF, Richards TJ, Sbeitan I, Donnelly SS, Glue P, Agarwala SS, Kirkwood JM. (2002). Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 8:2480–2487.
   PubMed Web of Science ®Google Scholar
• Israel BC, Blouin RA, McIntyre W, Shedlofsky SI. (1993). Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 36:229–235.
   PubMed Web of Science ®Google Scholar
• Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. (2006). Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34:1756–1763.
   PubMed Web of Science ®Google Scholar
• Jonkman JH, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B, De Noord OE, Guentert TW. (1989). Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 27:795–802.
   PubMed Web of Science ®Google Scholar
• Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM. (1998). Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 46:563–570.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T. (2005). Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos 33:619–622.
   PubMed Web of Science ®Google Scholar
• Le Vee M, Gripon P, Stieger B, Fardel O. (2008). Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos 36:217–222.
   PubMed Web of Science ®Google Scholar
• Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE 3rd. (2004). Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon alfa immunotherapy. J Natl Cancer Inst 96:1331–1342.
   PubMedGoogle Scholar
• MacQuillan GC, Mamotte C, Reed WD, Jeffrey GP, Allan JE. (2003). Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol 70:219–227.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Green MD. (2007). Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 47:1540–1554.
   PubMed Web of Science ®Google Scholar
• Mano Y, Usui T, Kamimura H. (2007). The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35:2040–2044.
   PubMed Web of Science ®Google Scholar
• Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. (2003). Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425–461.
   PubMed Web of Science ®Google Scholar
• Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL, Kliewer SA. (2000). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122–15127.
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. (2008). Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205–216.
   PubMed Web of Science ®Google Scholar
• Nakai K, Tanaka H, Hanada K, Ogata H, Suzuki F, Kumada H, Miyajima A, Ishida S, Sunouchi M, Habano W, Kamikawa Y, Kubota K, Kita J, Ozawa S, Ohno Y. (2008). Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos 36:1786–1793.
   PubMed Web of Science ®Google Scholar
• Pageaux GP, le Bricquir Y, Berthou F, Bressot N, Picot MC, Blanc F, Michel H, Larrey D. (1998). Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 10:491–495.
   PubMed Web of Science ®Google Scholar
• Petzinger E, Geyer J. (2006). Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch Pharmacol 372:465–475.
   PubMed Web of Science ®Google Scholar
• Poizot-Martin I, Marimoutou C, Benhaim S, Drogoul-Vey MP, Dinh T, Vion-Dury F, Frixon-Marin V, Tamalet C, Gastaut JA. (2003). Efficacy and tolerance of HCV treatment in HIV–HCV coinfected patients: the potential interaction of PI treatment. HIV Clin Trials 4:262–268.
   PubMed Web of Science ®Google Scholar
• Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, Cai H, Strom S, Liu Y, El-Assal O, Gao B. (2002). Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122:1020–1034.
   PubMed Web of Science ®Google Scholar
• Rose ML, Rusyn I, Bojes HK, Germolec DR, Luster M, Thurman RG. (1999). Role of Kupffer cells in peroxisome proliferator-induced hepatocyte proliferation. Drug Metab Rev 31:87–116.
   PubMed Web of Science ®Google Scholar
• Schäfer M, Schmidt F, Grunze H, Laakmann G, Loeschke K. (2001). [Interferon alpha-associated agranulocytosis during clozapine treatment. Case report and status of current knowledge]. Nervenarzt 72:872–875.
   PubMed Web of Science ®Google Scholar
• Shah I, Band J, Samson M, Young J, Robinson R, Bailey B, Lerner AM, Prasad AS. (1984). Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies. Am J Hematol 17:363–371.
   PubMed Web of Science ®Google Scholar
• Stanley LA, Adams DJ, Balkwill FR, Griffin D, Wolf CR. (1991). Differential effects of recombinant interferon alpha on constitutive and inducible cytochrome P450 isozymes in mouse liver. Biochem Pharmacol 42:311–320.
   PubMed Web of Science ®Google Scholar
• Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. (1998). How cells respond to interferons. Annu Rev Biochem 67:227–264.
   PubMed Web of Science ®Google Scholar
• Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD. (2004). Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32:359–363.
   PubMed Web of Science ®Google Scholar
• Tong Z, Chandrasekaran A, Jordan R, Markiewicz V, Li H, Xiang Q, Shen L, Scatina J. (2007). Effects of ertiprotafib on hepatic cytochrome P450 and peroxisomal enzymes in rats and dogs, and in rat and human primary hepatocytes. Xenobiotica 37:1–18.
   PubMed Web of Science ®Google Scholar
• Wan L, Lin CW, Lin YJ, Sheu JJ, Chen BH, Liao CC, Tsai Y, Lin WY, Lai CH, Tsai FJ. (2008). Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J Cell Mol Med 12:876–888.
   Google Scholar
• Wong SF, Jakowatz JG, Taheri R. (2005). Potential drug–drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. Clin Ther 27:1942–1948.
   PubMed Web of Science ®Google Scholar
• Xie W, Evans RM. (2001). Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 276:37739–37742.
   PubMed Web of Science ®Google Scholar